SAN DIEGO–(BUSINESS WIRE)– Crown Bioscience, een JSR Life Sciences-bedrijf, heeft vandaag aangekondigd dat het zijn commerciële leiderschapsteam heeft geherstructureerd door een nieuwe functie van Chief Business Officer (CBO) te creëren en met extra investeringen in commercieel talent.
Met onmiddellijke ingang wordt Michael Prosser gepromoveerd tot Chief Business Officer. Michael werkt al meer dan tien jaar bij Crown Bioscience in verschillende operationele en commerciële leiderschapsposities, en was meest recentelijk Senior Vice President, Commerciële en Strategische Ontwikkeling.
Voortbouwend op de aanhoudende groei van het bedrijf zijn er binnen het commerciële team drie nieuwe rollen gecreëerd die zullen rapporteren aan de heer Prosser. Alex Slater, die vorig jaar bij het bedrijf kwam werken, heeft als Vice President of Global Business Development extra verantwoordelijkheid voor de bedrijfsontwikkeling van APAC op zich genomen; Dr. Jonny McMichael is benoemd tot Vice President Client Experience and Enablement; en Dr. Achim Quandt is bij het bedrijf gekomen als Executive Director of Product Management.
Crown Bioscience Appoints Michael Prosser as Chief Business Officer and Illustrates Further Investment in Commercial Leadership
SAN DIEGO–(BUSINESS WIRE)– Crown Bioscience, a JSR Life Sciences company, announced today that it has restructured its commercial leadership team by creating a new Chief Business Officer (CBO) role and with additional investment in commercial talent.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220728005025/en/
Effective immediately, Michael Prosser is promoted to Chief Business Officer. Michael has been with Crown Bioscience for over ten years serving in a variety of operational and commercial leadership positions, and most recently served as Senior Vice President, Commercial and Strategic Development. (Photo: Business Wire)
Effective immediately, Michael Prosser is promoted to Chief Business Officer. Michael has been with Crown Bioscience for over ten years serving in a variety of operational and commercial leadership positions, and most recently served as Senior Vice President, Commercial and Strategic Development.
Building on the company’s continued growth, three new roles have been created within the commercial team and will report to Mr. Prosser. Alex Slater, who joined the company last year, has taken on added responsibility for APAC business development as Vice President of Global Business Development; Dr. Jonny McMichael has been appointed to Vice President of Client Experience and Enablement; and Dr. Achim Quandt has joined the company as Executive Director of Product Management.
“Crown Bioscience has grown significantly in recent years, consistently exceeding its annual growth target, and in FY21 we were delighted to record bookings growth of over 40%,” said Armin Spura, CEO. “With these changes announced today and under Michael’s continued leadership, we are confident we are putting in place a commercial team that optimally positions Crown Bioscience for our next phase of growth.”
Michael Prosser, CBO, stated: “It’s an honor to be asked to lead the next stage in Crown Bioscience’s commercial growth. Our success to date is directly attributable to our relentless focus on customer experience, product innovation, and setting new industry-leading quality standards, and I’m excited to be working closely with the new team and structure as we strive to continuously improve in all these areas.”
The company added more than four hundred new customers in FY21, and to meet increased customer demand, has accelerated investments in its global footprint, with renovations now complete in APAC laboratories, and notably the formation of a joint venture with sister company MBL in Japan. In Europe and the United States, parallel investments are also planned for site expansions and strategic acquisitions.
About Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) providing preclinical and translational platforms to advance oncology, immuno-oncology, and immune-mediated inflammatory diseases. The company is the only preclinical CRO to provide tumor organoid services utilizing HUB technology and has the world’s largest commercially available PDX collection. Crown Bioscience helps deliver superior drug candidates to ensure that patients get the right treatment at the right time. Founded in 2006, Crown Bioscience has nine facilities in the US, Europe and Asia. Find out more: https://www.crownbio.com.